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Anti-Thy1.1 transgenic mice develop glomerular lesions that mimic collapsing focal segmental 
glomerulosclerosis (fSGS) in humans with collapse of the glomerular tuft and marked hyperplasia 
of the parietal epithelial cells (PECs). Immunostaining of phosphor-S6 ribosomal protein (pS6RP) 
revealed high mtoR activity in pecs of the fSGS lesions of these mice. in this study we questioned 
whether the mtoR inhibitor rapamycin (sirolimus) could attenuate the development and progression 
of glomerulosclerotic lesions in the anti-Thy1.1 transgenic mice. We observed reduced mTOR signalling 
and proliferation in human parietal epithelial cells after rapamycin treatment. experiments with anti-
Thy1.1. mice showed that early treatment with sirolimus reduced the development of glomerular 
lesions and glomerular cell proliferation at day 4. Levels of albuminuria, podocyte injury and podocyte 
number were similar in the sirolimus and vehicle treated groups. The initial beneficial effects of sirolimus 
treatment were not observed at day 7. Late sirolimus treatment did not reduce albuminuria or the 
progression of glomerulosclerosis. taken together, rapamycin attenuated pec proliferation and the 
formation of early fSGS lesions in experimental fSGS and reduced human pec proliferation in vitro. 
However, the initial inhibition of pec proliferation did not translate into a decline of albuminuria nor in a 
sustained reduction in sclerotic lesions.
Focal segmental glomerulosclerosis (FSGS) is characterized by the formation of sclerotic lesions in the glomeruli 
of the kidneys. FSGS is one of the most common glomerular disorders and the leading cause of end-stage renal 
disease (ESRD) in the United States1. Several underlying conditions can lead to FSGS such as diabetes, hyper-
tension and obesity. In addition, FSGS can be caused by genetic mutations affecting the function of essential 
glomerular cell proteins or it can be idiopathic1,2. The diagnosis of FSGS is largely based on histopathological 
findings characterized by the adhesions of the Bowman’s capsule with the glomerular tuft, the formation of focal 
and segmental sclerotic lesions, obliteration of glomerular capillaries and extracellular matrix accumulation3,4. 
Currently, the different histological patterns of FSGS have been divided into five subvariants: the perihilar-, the tip -, 
the cellular-, the NOS (not otherwise specified)-, and the collapsing variant, latter is characterized by collapse of 
the glomerular tuft and PEC hyperplasia2.
The pathogenesis of FSGS is not completely unravelled. In the last decade we and others demonstrated that 
parietal epithelial cells (PECs) are crucially involved in the formation of sclerotic lesions. Genetic tagging of 
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podocytes or PECs in different models of FSGS showed that upon induction of glomerular injury PECs migrate to 
the capillary tuft and induce the adhesion between Bowman’s capsule and the tuft5,6. These activated PECs invade 
the injured area and deposit extracellular matrix that results in the progression of FSGS7,8. In addition, similar 
pathohistological patterns were observed in secondary FSGS that are independent of the underlying disease9. 
These findings strengthen the assumption that common molecular pathways lead to PEC activation and subse-
quently to FSGS formation and progression.
Hamatani and colleagues observed activation of the mammalian target of rapamycin (mTOR), a main player 
in cell proliferation and survival, specifically in PECs in experimental models of glomerular diseases. They 
observed that a reduction of the stress-inducible protein sestrin-2 in PECs was associated with increased pS6RP 
expression as well as de novo expression of the activation marker CD4410. The results from Hamatani et al. sug-
gested that mTOR signalling plays an important role in the switch from resting to activated PECs seen in progres-
sive glomerular disease. Therefore, mTOR might be a pharmaceutical target to prevent or reduce PEC activation 
and subsequently glomerulosclerosis formation.
In the present study we investigated this hypothesis and studied the effects of mTOR inhibition on immortal-
ized human parietal epithelial cells and in anti-Thy1.1 transgenic mice, a model resembling collapsing FSGS in 
humans.
Results
Rapamycin reduces mtoR signalling and cell proliferation of human parietal epithelial cells. 
Since we hypothesized that mTOR signalling is important for PEC proliferation in FSGS, we investigated the 
effect of the mTOR inhibitor rapamycin on cultured human immortalized PECs. The expression of pS6RP as 
readout for mTOR signalling and PEC proliferation was studied, when exposed to different concentrations of 
rapamycin or DMSO as control. Already at a concentration of 5 nM rapamycin the expression of the pS6RP 
was reduced (Fig. 1A, p < 0.001). The non-phosphorylated protein was not significantly affected (Fig. 1B). In 
addition, higher concentrations of rapamycin (≥30 µM) reduced PEC proliferation (Fig. 1C, p < 0.001). These 
findings show that rapamycin can target PECs directly in vitro. As PEC proliferation is described to be related to 
CD44 expression11, the effect of rapamycin on CD44 gene and protein expression was studied (Supplementary 
Fig. S1). The results indicate that the inhibition of PEC proliferation after rapamycin treatment is independent of 
the expression level of CD44.
mtoR activity is increased in sclerotic lesions. To study the effect of mTOR inhibition in PECs in 
vivo we used the transgenic anti-Thy1.1 mouse, an experimental model for collapsing FSGS. Injection of the 
anti-Thy1.1 antibody in the transgenic Thy1.1 mice results in an almost immediate development of albuminuria 
that peaks at day 1 after injection12. Within 7 days the FSGS lesions, that resemble collapsing FSGS and are asso-
ciated with hyperplasia of the PECs5,12,13, are formed. Early stages of the lesions can already be observed after 4 
days13.
Immunostaining of the podocyte marker synaptopodin, the PEC marker SSeCKS14 and pS6RP as marker for 
mTOR signalling revealed an increased pS6RP expression in PECs in the affected glomeruli of the anti-Thy1.1 
mice, while in morphologically normal glomeruli only few cells showed mTOR signalling (Fig. 2). These 
results suggest that increased mTOR activity may play a role in PEC activation and disease progression in the 
anti-Thy1.1. mice.
Sirolimus treatment does not reduce albuminuria and podocyte damage. We evaluated in the 
anti-Thy1.1 mouse model the effect of sirolimus on the development of the first visible glomerular lesions at day 
4 and the fully developed lesions at day 7. Following sirolimus treatment, albuminuria was not reduced at day 4 
(Fig. 3A) and day 7 (Fig. 3B), while binding of the anti-Thy1.1 antibody was equal in the sirolimus and phosal 
(vehicle) treated mice (data not shown). Immunofluorescent staining for synaptopodin and the podocyte injury 
marker desmin (Fig. 3C–E) showed no differences in the amount of podocyte injury between the phosal and 
sirolimus treated mice at day 4 (Fig. 3F). In addition, immunofluorescent staining for DACH1 in combination 
with synaptopodin (Fig. 3G–I) revealed that the number of podocytes was similar in sirolimus and phosal treated 
mice (Fig. 3J). These results indicate that early mTOR inhibition did not have an effect on the degree of podocyte 
injury, podocyte number and proteinuria in the anti-Thy1.1 mouse model.
Sirolimus reduces glomerular damage and cell proliferation at day 4. Despite similar levels of 
albuminuria and podocyte injury between the phosal and sirolimus treated mice, we observed less affected glo-
meruli in mice treated with sirolimus compared to the control mice at day 4 (Fig. 4A). Glomeruli were considered 
affected when they showed one of the following histological changes: vacuolization of the epithelial cells, hyalin-
osis or epithelial cell hyperplasia (Supplementary Fig. S2). The majority of phosal treated mice had a more severe 
histological phenotype showing more protein casts and affected glomeruli (Fig. 4C). The affected glomeruli of 
sirolimus treated mice mainly appeared with vacuolization and mild cell proliferation. However, the greatest part 
of glomeruli was unaffected (Fig. 4E). In addition, we detected fewer proliferating (ki-67 positive) cells in the 
Bowman’s space in sirolimus treated mice, indicating less PEC proliferation (Fig. 4B, D, F). The sirolimus treated 
mice also showed fewer proliferating cells in the glomerular tuft (Fig. 4B). As proliferating endothelial cells were 
identified in the mice (Supplementary Fig. S3), their proliferation was probably also reduced due to sirolimus 
treatment. In vitro we showed that rapamycin indeed has a direct effect on the glomerular endothelial cell prolif-
eration (Supplementary Fig. S4).
Sirolimus does not reduce glomerular damage and cell proliferation at day 7. As sirolimus 
reduced PEC proliferation and the formation of lesions during the early proliferative phases of FSGS develop-
ment, we next investigated whether early sirolimus treatment sustained reduction of sclerotic lesions. However, 
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the number of affected glomeruli at day 7 in the phosal and sirolimus treated groups was similar (Fig. 5A). 
Histological analysis revealed that hyalinosis was clearly visible in the glomeruli and that tubular protein casts 
could be observed in both the phosal and sirolimus treated mice. In addition, the majority of affected glomeruli 
showed extensive PEC proliferation (Fig. 5C–F). Notably, the sirolimus treated mice showed the highest number 
of ki-67 positive cells in Bowman’s space (Fig. 5B).
Sirolimus treatment after glomerulosclerosis development does not reduce albuminuria and 
sclerosis. To evaluate whether mTOR inhibition can attenuate the progression of glomerulosclerosis in a later 
phase of disease development, we performed an experiment treating anti-Thy1.1 mice daily with sirolimus or 
phosal for a period of 20 days. Knowing that sclerotic lesions are formed within the first 7 days after anti-Thy1.1 
antibody injection13, we started sirolimus and phosal treatment at day 11. Comparing the albuminuria levels 
of the sirolimus and phosal treated mice, no significant differences could be observed (Fig. 6A). Furthermore, 
Figure 1. Rapamycin inhibits mTOR signalling and cell proliferation of human immortalized PECs. (A) mTOR 
signalling is presented as pS6RP expression. Protein expression of pS6RP was significantly reduced in PECs 
treated with 5nM-10µM rapamycin compared to cells treated with 0.02% (v/v) DMSO (vehicle) for 24 hours. 
Quantitative analysis was performed using the results of blots of 3 different experiments (n = 3). An example  
of the protein expression of γ-tubulin and pS6RP of one of the three western blots is shown underneath the 
graph. Protein expression is shown from cells treated with the DMSO control and 5 nM–10 µM rapamycin. 
The signal of γ-tubulin and pS6RP shown are cropped and marked with a black box. All full-length blots 
are presented in Supplementary Fig. S5. (B) No significant reduction of the non-phosphorylated S6RP was 
observed in rapamycin treated cells after 24 hours. Quantitative analysis was performed using the results of 
blots of 3 different experiments (n = 3). An example of the protein expression of γ-tubulin and S6RP of one 
of the three western blots is shown underneath the graph. Protein expression is shown from cells treated with 
the DMSO control and 5 nM-10 µM rapamycin. The signal of γ-tubulin and S6RP shown are cropped and 
marked with a black box. All full-length blots are presented in Supplementary Fig. S6. (C) Cell proliferation was 
significantly inhibited by rapamycin (30 µM, 50 µM, 24 hours) compared to controls. Mean with SEM is shown 
(n = 3). ***P ≤ 0.001, ns P ≥ 0.05.
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the number of sclerotic glomeruli was similar (Fig. 6B). In general, the kidney tissue of all mice showed influx 
of immune cells in the glomeruli and the interstitium. Hyalinosis and collapsing tufts could be detected in the 
glomeruli (Fig. 6C, D). Some glomeruli still displayed some PEC proliferation. The results indicate that mTOR 
inhibition did not have an effect on the glomerular pathology once the glomerular lesions are formed. In general, 
our findings indicate that sirolimus reduces PEC proliferation and formation of lesions in the early proliferative 
phase of FSGS development but cannot prevent the further development of glomerulosclerosis.
Discussion
In this study, we tested the hypothesis that mTOR signalling regulates PEC activation and that mTOR inhibition 
may prevent PEC proliferation and subsequently glomerulosclerosis in the anti-Thy1.1 mouse model, an experi-
mental model of collapsing FSGS.
We observed an increased mTOR activity, expressed as the phosphorylation of S6RP, in affected glomeruli 
of the anti-Thy1.1 mice. Especially PECs showed a striking increase in pS6RP expression. Sirolimus treatment 
reduced the number of affected glomeruli, which was associated with less PEC proliferation, in the early lesions 
seen at day 4. The reduced PEC proliferation could be a direct effect of rapamycin on PECs, since also rapamycin 
treated PECs in culture showed reduced pS6RP levels and reduced proliferation. In addition, the effects on PECs 
were independent of podocytes as the sirolimus treatment did not have an effect on albuminuria, the number of 
Figure 2. Increased pS6RP expression in parietal epithelial cells in sclerotic glomeruli. (A, C, E) Representative 
images of a morphological normal glomerulus of an anti-Thy1.1 mouse 4 days after disease induction. SSeCKS 
(green, A, E), pS6RP (red, C, E) and synaptopodin (violet, E) expression is shown. pS6RP expression was 
observed in some SSeCKS positive cells (arrow) and in some synaptopodin positive podocytes (arrowhead) and 
outside of the glomerulus (asterisk). (B, D, F) Representative images of a sclerotic glomerulus of an anti- Thy1.1 
mouse 4 days after disease induction. In sclerotic glomeruli an increased pS6RP expression in SSeCKS positive 
PECs was observed (arrows). pS6RP expression could also be detected outside of the glomerulus (asterisk).
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Figure 3. Sirolimus treatment of experimental FSGS did not change albuminuria, podocyte injury and 
podocyte number. (A) Sirolimus treated mice did not show a lower albumin/creatinine ratio compared to 
control mice at day 4 and (B) day 7. Sirolimus treated mice n = 12, phosal treated mice n = 8. Mean with SD 
is shown. ns P ≥ 0.05. (C, D, E) Representative images of glomeruli stained against synaptopodin (C, D, red) 
and desmin (C, E, green). (C) A healthy glomerulus (a) only shows desmin expression in the mesangial cells. 
In diseased glomeruli (b) desmin staining can also be detected in podocytes (co-localizing with synaptopodin 
expression (C, yellow, arrow)). (F) Glomerular desmin expression was similar in the sirolimus and control 
group. Sirolimus treated mice n = 4, phosal treated mice n = 4. Mean with SD is shown. ns P ≥ 0.05. (G, H, I) 
Representative images of glomeruli stained against synaptopodin (G, H, red) and DACH1 (G, I, yellow). (G) A 
line was drawn surrounding the tuft area to measure it. The whole tuft area was selected also in case no or less 
synaptopodin signal was present (example glomerulus a). (J) Phosal and sirolimus treated mice have a similar 
number of DACH1 positive podocytes per mm2 of the tuft area. Sirolimus treated mice n = 6, phosal treated 
mice n = 6. Mean with SEM is shown. ns P ≥ 0.05.
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podocytes or podocyte injury. However, despite the marked effects of rapamycin in culture and in the develop-
ment of the early lesions in the mice, continuation of the treatment with sirolimus could not prevent glomerulo-
sclerosis at day 7. Also sirolimus treatment after sclerosis development could not reduce lesion formation.
Recent studies indicated that in the formation of lesions in FSGS and crescentic glomerulonephritis the PECs 
become activated5,9. The normal quiescent flat cells become enlarged and show different marker expression, i.e. a 
de novo expression of CD448,11,15. Although, we and others have established the involvement of PECs in the devel-
opment of glomerular lesions, still little is known about the molecular processes driving PEC activation16. Several 
studies have described a role for mTOR in glomerular disease models. Although, most of these studies focused on 
mTOR signalling in podocytes17–21, a few studies have studied the pathway in PECs10,22,23. These studies indicated 
that mTOR signalling might be involved in PEC activation and therefore the development of sclerotic lesions.
This study shows a link between mTOR signalling and PEC activation as well. Inhibiting mTOR in the 
anti-Thy1.1 mice reduced PEC proliferation and sclerosis formation at day 4. However, it was striking that the 
beneficial effects of mTOR signalling were not seen in later phases of the disease. These contradictory findings 
can also be seen in other studies that investigated mTOR signalling in PECs. In general, all studies, including this 
Figure 4. Sirolimus treatment reduced glomerular damage and cell proliferation at day 4 in experimental 
FSGS. (A) Sirolimus treated mice showed significant less affected glomeruli compared to phosal treated mice. 
At least 55 glomeruli per mouse were scored. Sirolimus treated mice n = 11, phosal treated mice n = 10. (B) 
Proliferation is expressed as ki-67 positive cells per glomerulus. Ki-67 positive cells were counted in at least 
55 glomeruli per mouse. Cell proliferation in the tuft and in the Bowman’s space was significantly reduced at 
day 4. Sirolimus treated mice n = 12, phosal treated mice n = 10. (C, E) Representative images of glomeruli 
stained with PAS of phosal and sirolimus treated mice. Arrows indicate vacuolization in the glomerulus. 
(D, F) Representative images of glomeruli stained with ki-67 (brown colour) and PAS without hematoxylin 
stain. Arrows indicate cell proliferation in the Bowman’s space, arrowheads indicate cell proliferation in the 
glomerular tuft. Mean with SEM is shown. *P ≤ 0.05, ***P ≤ 0.001.
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work, showed that the effects of mTOR inhibition are dependent on the dose of the mTOR inhibitor, the animal 
model used, the route of administration and on the onset and duration of treatment.
Similar to our observations, Kurayama et al. showed that the outcome of mTOR inhibition is dependent on 
the onset and duration of the mTOR inhibition. The study demonstrated that in a rat model of crescentic nephri-
tis early treatment (day of disease induction) with everolimus led to increased cellular necrosis. However, later 
treatment (7 days after disease induction) reduced glomerular crescent formation22. Since the anti-Thy1.1 model 
and the nephritis model are different models of treatment strategies and time, the observed effects are difficult to 
compare to our findings. Nevertheless, both studies show that the timing of treatment is critical.
Besides the timing, also the dose of rapamycin is of importance for the treatment results. From seminal studies 
performed by Gödel and co-workers it has become clear that mTOR signalling is tightly regulated and that an 
imbalance in mTOR activity may lead to adverse effects, facilitating glomerular disease17. In their study Gödel 
and colleagues deleted the regulatory-associated protein (Raptor), an essential adaptor molecule of mTOR, 
Figure 5. Sirolimus does not reduce cell proliferation and sclerosis at day 7 in experimental FSGS. (A) 
Sirolimus treated anti-Thy1.1 mice showed no significant differences in the percentage of affected glomeruli 
compared to phosal treated mice. At least 55 glomeruli per mice were scored. Sirolimus treated mice n = 13, 
phosal treated mice n = 9. (B) Proliferation is expressed as ki-67 positive cells per glomerulus. Ki-67 positive 
cells were counted in at least 55 glomeruli per mouse. Sirolimus treated mice showed similar cell proliferation 
in the tuft and more cell proliferation in the Bowman’s space compared to phosal treated mice. Sirolimus treated 
mice n = 13, phosal treated mice n = 9. (C, E) Representative images of glomeruli stained with PAS of phosal 
and sirolimus treated mice. Black arrows indicate vacuolization of the glomerulus. White arrows indicate PEC 
proliferation. Hyalinosis deposits can be observed in the capillary tuft (dark violet). (D, F) Representative 
images of glomeruli stained with ki-67 (brown colour) and PAS without hematoxylin stain. Arrows indicate cell 
proliferation in the Bowman’s space, arrowhead indicates cell proliferation in the glomerular tuft. Dark violet 
colour in the capillary tuft indicates hyalinosis. Mean with SEM shown. *P ≤ 0.05, ns P ≥ 0.05.
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in podocytes of diabetic mice. They demonstrated that complete reduction of mTORC1 in RaptorΔpodocyte mice 
resulted in proteinuria and the progression of diabetic nephropathy, while deletion of only one allele of Raptor 
(RaptorHet podocyte) inhibited mTOR activation, leading to decreased proteinuria and glomerulosclerosis17. Hence, 
it was demonstrated that complete reduction of mTOR activity can be responsible for the progression of glomer-
ular injury. This means that the reduction of mTOR activity to prevent disease progression should be done with 
care, as a too strong reduction can have deleterious effects. This conclusion can also be drawn from a similar study 
performed by Zschiedrich et al. They showed that a homozygous podocyte specific knockout (KO) of Raptor in 
an adriamycin induced nephropathy mouse model caused massive proteinuria and sclerosis, while a heterozygous 
KO resulted in a reduction of proteinuria and sclerosis21. They also showed that a high dose of administered rapa-
mycin has a similar effect as a complete Raptor KO, while low rapamycin concentrations resembled the beneficial 
outcome of the heterozygous KO, again stressing the tight regulation of mTOR in the glomerulus.
The possible decrease in endothelial proliferation due to mTOR inhibition might have contributed to the 
recurrent sclerosis formation observed in our experiment, as reduced endothelial cell proliferation presumably 
impairs endothelial repair of capillaries that normally is required after glomerular damage due to anti-Thy1.1 
injection24.
Due to the narrow therapeutic window of sirolimus, and in the murine studies described problems of treat-
ment onset and duration, the implementation of sirolimus into the clinic to treat glomerulosclerosis will be 
challenging. Sirolimus and other rapamycin analogues (rapalogous) are approved by the Food and Drug admin-
istration (FDA) for the treatment of cancers, transplant rejection, lymphangioleiomyomatosis and tuberous 
sclerosis complex25. Therapeutic effects of sirolimus or rapalogous are often hampered due to recurrence of the 
disease assumably caused by negative feedback loops. To prevent this, treatments combining sirolimus with 
drugs targeting the pathways involved in the negative feedback (e.g. Akt pathway), seem more promising25. Also, 
ATP-competitive mTOR inhibitors are developed that prevent the feedback-mediated Akt activation26. Although 
the treatment with mTOR inhibitors can have beneficial effects, it is often accompanied with severe side effects 
such as haematological abnormalities, nephrotoxicity, dermatological diseases, impaired wound healing and met-
abolic disorders27, which makes long lasting treatment difficult.
In conclusion, this study shows that rapamycin can have a direct effect on parietal epithelial cells, which in 
vivo can lead to a short-lasting reduction of PEC proliferation and sclerotic lesions. Our findings point out that 
an elevated mTOR expression in parietal epithelial cells might contribute to PEC activation and the formation 
Figure 6. Late sirolimus treatment did not attenuate albuminuria and glomerulosclerosis in anti-Thy1.1 
mice at day 31. (A) Albumin/creatinine ratio of phosal and sirolimus injected mice. No significant differences 
between the mice could be measured over time. Sirolimus treated mice n = 14, phosal treated mice n = 15. 
(B) The number of sclerotic glomeruli was not significant different between the sirolimus treated and control 
mice (day 31). At least 71 glomeruli per mouse were scored. Sirolimus treated mice n = 14, phosal treated mice 
n = 11. (C, D) Representative images of glomeruli stained with PAS of a (C) phosal treated mouse and a (D) 
sirolimus treated mouse. The histology between the phosal and sirolimus treated mice was comparable showing 
glomerulosclerosis (arrows), hyalinosis (asterisks) and PEC hyperplasia (arrowhead). Mean with SEM shown. 
ns P ≥ 0.05.
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of glomerulosclerosis. However, literature and this study show that within the glomerulus mTOR signalling is 
tightly regulated, resulting in a narrow therapeutic window of rapamycin. When not used in optimal concen-
trations, as well as in the favourable time window for treatment, mTOR inhibition can have no beneficial or 
even deleterious effects. In addition, systemic administration of the inhibitor may have non-specific effects, 
decreasing mTOR inhibition in other cells resulting in for instance prevention of normal kidney repair functions. 
Whether ATP-competitive mTOR inhibitors or combination treatments of sirolimus and drugs targeting path-
ways involved in negative feedback loops could decrease sclerosis formation permanently evoking tolerating side 
effects has to be investigated.
Material and Methods
cell culture. Immortalized polyclonal human parietal epithelial cells (hPECs) were cultured as described in 
Kietzmann et al.28. HPECs were differentiated for 2 weeks at 37 °C, 5% (v/v) CO2. Conditionally immortalized 
glomerular endothelial cells (ciGENCs, clone 1D4) were kindly provided by Simon C. Satchell29. Details about the 
culture conditions can be found online in the supplementary materials.
Animal studies. All experiments were performed using 6–8 weeks old male Thy1.1 transgenic mice from 
own breeding. These mice have been backcrossed into the C57BL/6 J for 10 generations. The animal experiments 
were approved by the Animal Ethics Committee of the Radboud University Nijmegen and performed in accord-
ance with the European Communities Council Directive (86/609/EEC). The setup of the animal experiments is 
shown in Fig. 7. More details can be found online in the supplementary materials.
Albumin/creatinine ratio (AcR). Urine albumin of the mice was determined using the Mancini immuno-
diffusion method. The creatinine values were determined at the Radboudumc laboratory of diagnostics (RLD), 
Radboudumc, Nijmegen, the Netherlands, using a modulation analyser Cobas C8000-1/-2 (Roche Diagnostics).
Western blotting. RIPA buffer (Cell signaling, #9806) supplemented with 1 mM protease inhibitor phenyl-
methylsulfonyl fluoride (PMSF) was used for protein extraction of hPECs and ciGENCs. Protein concentrations 
were determined using the Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific). Samples were prepared 
using 4x Laemmli buffer (Bio-Rad) supplemented with beta-mercaptoethanol. Per sample, 25 µg protein was 
loaded on a 12% (v/v) Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) gel and trans-
ferred to a nitrocellulose membrane. Antibodies used to detect the pS6RP, the S6RP and the housekeeping gene 
γ-tubulin are shown in Table 1. These antibodies are well established and commonly used18,19,21,30–33. The fluo-
rescent signal was analysed with the Odyssey Imaging System (LI-COR Biosciences) and Odyssey Image studio 
Software (version 4.0).
Bromodeoxyuridine (BrdU) assay. We performed the BrdU proliferation ELISA, according to manufac-
turer’s protocol (BrdU Cell Proliferation ELISA Kit, Abcam, ab126556). Cells were treated with different rapa-
mycin concentrations and their respective DMSO controls for 24 hours. The BrdU antibody was incubated for 
15 hours. The hPECs were seeded in a density of 20,000 cells/cm2 two days prior to rapamycin or DMSO expo-
sure, ciGENCs were seeded in a density of 20,000 cells/cm2 4 days before starting the experiment.
tissue staining. All stainings were performed on 4 µm formalin-fixed paraffin-embedded (FFPE) kidney 
sections. Antigen retrieval was performed in citrate buffer (pH 6) or Tris-EDTA buffer (pH 9) at boiling point for 
Figure 7. Schematic diagram of the in vivo experiments. (A) 72 hours prior to anti-Thy1.1 antibody injection 
animals were daily treated with sirolimus or phosal (vehicle). At day 4, urine was collected from the first group 
and these mice were sacrificed. Group 2 received treatments for additional 3 days. At day 7, urine was collected 
from group 2 and these mice were sacrificed. (B) Transgenic Thy.1.1 mice were injected with the anti-Thy1.1 
antibody and urine was collected after 10 days. From day 11 onwards, mice were treated with sirolimus or the 
vehicle daily. Additional urine was collected at day 17, day 24 and day 31. Mice were sacrificed at day 31.
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13 minutes. Details about primary- and matching secondary antibodies used are described in Table 1. Fluorescent 
stained slices were mounted in DAPI Fluoromount-G® (SouthernBiotech). Co-staining of synaptopodin and 
desmin was performed to detect injured podocytes. The synaptopodin antibody used was detected with Alexa 
Fluor donkey anti-goat 546 followed by a 10% (v/v) goat serum in PBS blocking step. Next, the secondary anti-
body against desmin was applied. To assess pS6RP in podocytes and PECs a triple staining was performed. The 
P-S6 Ribosomal Protein (S235/236) antibody was visualized using the Tyramide Signal Amplification (TSA) kit 
#16 (Molecular probes, life technologies, T20926). Subsequently podocytes and PECs were stained with antibod-
ies against synaptopodin and SSeCKS, respectively. To detect proliferating endothelial cells, sections were incu-
bated with CD34 and ki-67 antibodies. Secondary antibodies were used as shown in Table 1. For the detection of 
podocyte nuclei, sections were incubated with the nuclear marker DACH1 combined with the podocyte maker 
synaptopodin. The tuft area was measured using CaseViewer software (3DHISTECH Ltd.) and DACH1 positive 
cells in the glomeruli were counted. A minimum of 48 glomeruli and a maximum of 110 glomeruli per mouse 
were scored. From each scored glomerulus we calculated the ratio of DACH1 positive podocytes per tuft area 
(mm2) and took the average of these ratios for each mouse.
For detecting ki-67 positive cells immunohistochemically, endogenous peroxidases as well as endogenous 
biotin, biotin receptors, and avidin were blocked using 3% (v/v) hydrogen peroxide and the Avidin/Biotin 
blocking Kit (Vector laboratories SP-2001). As primary antibody anti-ki-67 antibody (Table 1) was used, which 
was detected using a biotinylated Goat Anti-Rabbit IgG Antibody (Vector Laboratories, BA-1000) and the 
VECTASTAIN® Elite®ABC-HRP Kit (Vector laboratories, PK-6100). The 3,3′-diaminobenzidine (DAB) horse-
radish peroxidase was used as substrate. Periodic acid–Schiff (PAS) staining without haematoxylin stain was 
performed afterwards. Per mouse, the ki-67 positive cells were counted in a minimum of 57 and a maximum of 
114 glomeruli.
A PAS staining was performed to identify affected glomeruli. A minimum of 58 glomeruli and a maximum of 
122 glomeruli per mouse were scored.
Statistics. The differences between sirolimus and phosal treated mice concerning podocyte count, glomer-
ular proliferation, the percentage of affected glomeruli and desmin expression was statistically tested using a 
two-tailed Mann-Whitney U test with a confidence interval of 95%. Differences in the albumin/creatinine ratio 
was tested using a 2-way ANOVA including a Bonferroni post-test for the first experiment and for the second 
experiment a two-tailed Mann-Whitney U test was used. For the in vitro results we used a One-way ANOVA with 
a Bonferroni’s Multiple Comparison Test. A P value below 0.05 was considered as significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request. Additional information and data is available from the corresponding author on 
reasonable request.
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Primary antibody Dilution Secondary antibody Dilution
P-S6 Ribosomal Protein (S240/244) Rabbit Antibody (Cell 
Signaling, 2215 S) 1:1,000
Alexa Fluor 680 goat anti-rabbit IgG (H + L) (Life 
technologies, A21076) 1:10,000
S6 Ribosomal Protein (5G10) Rabbit monoclonal 
Antibody (Cell Signaling, 2217) 1:5,000
Alexa Fluor 680 goat anti-rabbit IgG (H + L) (Life 
technologies, A21076) 1:10,000
Anti-γ-tubulin antibody produced in mouse, (Sigma-
Aldrich, Clone GTU-88, T6557) 1:10,000
Alexa Fluor 790 donkey anti-mouse IgG (H + L) 
(Thermo Fischer Scientific, A11371) 1:10,000
Synaptopodin (goat-anti human, sc-21537, Santa Cruz) 1:200
Alexa Fluor donkey anti-goat 546 (11056, 
ThermoFisher), Alexa Fluor donkey anti-goat IgG 
488 (H + L) (A11055 ThermoFisher)
1:200
Desmin (mouse IgG1, DAKO, M076) 1:200
Alexa Fluor goat anti-mouse 488 (IgG1) (A21121, 
ThermoFisher), 4% mouse serum added to PBS-
BSA (1% (w/v))
1:200
P-S6 Ribosomal Protein (S235/236)(Rabbit Ab, #2211 S, 
Cell signaling) 1:100
HRP conjugated stock solution (goat –anti 
rabbit HRP conjugated antibody, diluted 30 min 
incubation, Tyramide antibody (label 647), diluted 
in amplification buffer, 10 min incubation
HRP: 1:100
Tyramide: 1:100
SSeCKS (made in rabbit, kindly provided by Prof E. 
Gelman) 1:500
Alexa Fluor donkey anti-rabbit IgG 568 (H + L) 
(A10042 ThermoFisher) 1:200
CD34 anti-mouse antibody (CD34, Mouse, mAb 
MEC14.7, Rat IgG2a, HM1015) 1:100
Alexa Fluor goat anti-rat 647 (H + L) (A21247, 
Thermofischer) 1:200
Ki-67, Rabbit Monoclonal Antibody, clone sp6, RM-
9106-S, Thermo Scientific) 1:100
Alexa Fluor donkey anti-rabbit 488 (H + L) 
(A21206, Thermofischer) 1:200
DACH1 antibody (HPA012672, Sigma-Aldrich) 1:100 Alexa Fluor donkey anti-rabbit (H + L) (A3157, Thermofischer) 1:200
Table 1. Primary and secondary antibodies used for western blotting and tissue staining.
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